A drug-resistant ‘Japanese fungus’ has hit recent headlines when 200 patients were found to be infected or carrying the virus across 55 UK hospitals.
Hospitals have been forced to undergo intensive deep cleans, complex control measures and patient screenings; while one hospital was forced to close their intensive care unit due to the outbreak.
While healthy humans can usually fight off the fungus, hospital patients with a low immune system are prone to contracting a bloodstream infection which can cause major disabilities such as hearing loss.
The ‘Japanese fungus’ is Candida Auris. Candida Auris is actually a yeast. Yeasts are a type of fungus just like mould. Moulds and fungus release spores into the atmosphere. This is how they spread; through cross contamination. Just like other microbes ‘fungus’ is able to develop resistance to medicines that have traditionally proven effective in killing them.
Traditional anti-fungal medications target microbes in one place and act in a singular way. However, our antimicrobial BioCote silver-ion technology which is embedded into all our BioClad antimicrobial products has a multi-modal approach.
BioCote’s multi-modal approach works and acts in various ways simultaneously, meaning it is impossible for microbes like fungus or bacteria to develop resistance. The silver-ion technology works to kill these microbes by 99.99% to stop the spread of fungus like Candida Auris.
Antimicrobial expert Guy Charteris said: “BioCote have tested treated materials against Candida Auris and have been proven effective against it.
“The antimicrobial performance of BioCote protected products has been proven in many environments where hygiene is critical – hospitals, care homes, a food processing plant and schools. Our technology is proven effective against a broad spectrum of microbes including multi-drug resistant strains of bacteria, mould, fungus and even the H1N1 virus.”